explore -WSS

explore

author：comprehensive 2025-10-01 21:37:38 - browse：56932

Each COVID-19 vaccine vial from various companies is placed on individual rectangular backgrounds. Pfizer-BioNTech is positioned in the middle on a purple block adorned with two glitter star stickers, Moderna is on the top right on a red block, Janssen is on the bottom right on a blue block, and AstraZeneca is on the left on a red block. — Illustration: Christine Kao/STAT; Photos: Getty

It’s been four years since Covid-19 emerged, igniting a pandemic that killed millions of people and brought the world to its knees. A key factor in taming the pandemic was the creation of effective vaccines, which have saved millions of lives.

You’d think developing a successful vaccine would be an unmitigated win, from a financial perspective. And, indeed, for Pfizer and its partner BioNTech, as well as for Moderna — whose vaccines were the most widely used in the United States and much of the world — the revenues generated were absolutely staggering. But investors have shrugged at those sales as gains that will not be repeated.

Total sales of the Pfizer/BioNTech vaccine surpassed $80 billion, and more than 400 million doses of the shot and subsequent boosters have been administered in the U.S. alone. But the company’s stock price fell 32% over the past five years. Meanwhile, AstraZeneca, which told STAT it has not booked sales from its vaccine since last April and does not expect future sales, has seen its share price rise 64%. Merck, which saw its vaccine efforts fail twice, is up 56%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Pregnancy discrimination could be enabled by AI

WSS

AI models in health care face new federal disclosure requirements

Patients' immediate access to test results puts radiologists in a bind

FDA approves world's first CRISPR

The woman behind the Dana Farber

Be careful with at

Chemotherapy shortages won’t get better under Biden’s latest plan

focus

explore

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

Patients, digital health players weigh in on FTC's data privacy plan

The cancer drug shortage isn’t new — and neither are the solutions

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Continuity nursing helped my family in our darkest PICU moments

FDA needs staff influx to meet gene therapy needs, Marks says

How one medical school became remarkably diverse

Pharma patents targeted by Biden in move to slash drug prices

As demand for Covid shots wanes, Moderna seeks its next success

Pfizer plans to depart BIO

Wikipedia

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Spinal cord stimulation reduces pain in amputees, study finds

After Optum profits sink, UnitedHealth makes changes

CMS should re

What to know about the judge who will handle the Trump case

Surge in Apellis stock fueled by confidence in safety of its eye drug

Wikipedia

knowledge

hotspot

hotspot